Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration

Acta Ophthalmologica

Volumn 91, Issue 3, 2013, Pages

  Krebs, Ilse ^a,b   Vécsei Marlovits, Veronika ^c   Bodenstorfer, Johannes ^d   Glittenberg, Carl ^a,b   Ansari Shahrezaei, Siamak ^a,b   Ristl, Robin ^e   Binder, Susanne ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c Hietzing Hospital   (Austria)

^d Social Medical Center East   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

age related macular degeneration; choroidal neovascularization; photodynamic therapy (Verteporfin ); Ranibizumab (Lucentis ); vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN; VERTEPORFIN;

ADULT; AGED; AUSTRIA; BIOMICROSCOPY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; FLUORESCENCE ANGIOGRAPHY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MICROSCOPY, ACOUSTIC; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84876406363     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12018     Document Type: Review

References (27)

1. Antoszyk AN, Tuomi L, Chung CY, &, Singh A, (2008): Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145: 862-874.
2. Bashshur ZF, Schakal AR, El-Mollayess GM, Arafat S, Jaafar D, &, Salti HI, (2011): Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina 31: 636-644.
3. Bressler NM, (2001): Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119: 198-207.
4. Bressler NM, (2002): Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 133: 168-169.
5. Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, &, Kim RY, (2010): Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol 4: 1073-1079.
6. Cohen SY, Oubraham H, Uzzan J, Dubois L, &, Tadayoni R, (2012). Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina 32: 1480-1485.
7. Francis PJ, (2011): The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the lucentis genotype study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 109: 115-156.
8. Fung AE, Lalwani GA, Rosenfeld PJ, et al., (2007): An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
9. Holz FG, Korobelnik JF, Lanzetta P, et al., (2010): The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51: 405-412.
10. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, &, Acharya NR, (2007): Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
11. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, & DENALI Study Group (2012): Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration: twelve-Month Results of the DENALI Study. Ophthalmology 119: 1001-1010.
12. Kiss CG, Simader C, Michels S, &, Schmidt-Erfurth U, (2008): Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. Br J Ophthalmol 92: 1620-1627.
13. Krebs I, Hagen S, Smretschnig E, Womastek I, Brannath W, &, Binder S, (2011a): Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. Br J Ophthalmol 95: 1552-1554.
14. Krebs I, Smretschnig E, Moussa S, Brannath W, Womastek I, &, Binder S, (2011b): Quality and reproducibility of retinal thickness measurements in two spectral-domain optical coherence tomography machines. Invest Ophthalmol Vis Sci 52: 6925-6933.
15. Kumar A, Gopalakrishnan K, &, Sinha S, (2008): Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study. Retina 28: 1132-1137.
16. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al., (2012): Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration:twelve-month MONT BLANC Study Results. Ophthalmology 119: 992-1000.
17. Lim JY, Lee SY, Kim JG, Lee JY, Chung H, &, Yoon YH., (2012): Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 90: 61-67.
18. Menghini M, Kurz-Levin MM, Amstutz C, Michels S, Windisch R, Barthelmes D, &, Sutter FK, (2010): Response to ranibizumab therapy in neovascular AMD-an evaluation of good and bad responders. Klin Monbl Augenheilk 227: 244-248.
19. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al., (2011): Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 31: 662-668.
20. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, &, Shams N, (2008): Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, & MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
22. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, &, Tuomi L., (2012): HORIZON: an Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ophthalmology 119: 1175-1183.
23. Spielberg L, &, Leys A, (2010): Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol 248: 943-956.
24. Tolentino M, (2011): Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56: 95-113.
25. Ueta T, Yanagi Y, Tamaki Y, &, Yamaguchi T, (2009): Cerebrovascular accidents in ranibizumab. Ophthalmology 116: 362.
26. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, &, Bailey CC, (2010): A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye 24: 1561-1567.
27. Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, &, Wolf S, (2011): Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol 89: 585-590.